Our data shows that some chimeric RNAs, such as NSFP1-LRRC37A2, occur at frequency in line with other therapeutic targets such as HER2/neu in breast cancer and EGFR in lung cancer, opening the door to an “off the shelf” peptide vaccine targeting tumors with these alterations, similar to targeted therapeutic strategies in breast and lung cancer. This evidence concerns the gene ERBB2 and lung carcinoma.